Tanvex BioPharma   Report issue

For profit Phase 3
Founded: Taipei Taiwan (2014)

Organization Overview

First Clinical Trial
2018
NCT03556358
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Tanvex BioPharma USA, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 4